Back to Latest NewsPast News Archives2023 Breakthrough Results: Defence’s ARM™ Vaccine Cured 100% Of Animals With Pre-Established LymphomaDefence’s Succesfull Accutox™ Pre-Clinical Efficacy Study Complete Ready For Phase I Ind FilingUspto Grants Trademark Registration For Defence Therapeutics®Defence Granted Us Patent With Broad Coverage On Accumtm-Based Vaccine Enhancer Platform Technology Defence's Novel Accumtm-Mrna Vaccine Now Administered For Testing On CancerDefence Breakthrough: Successfully Engineered Accumtm -Mrna Vaccine Creating A New Vaccine Platform. The In Vivo Accumtm-Mrna Cancer Vaccine Program BeginsDefence To Complete A Final Pre-Clinical Study Prior To Ind Filings For The Accutoxtm Phase I Cancer Trial At The City Of Hope National Medical Center And Beckman Research InstituteDefence therapeutics announces exercise of warrants for gross proceeds of over $5 million Defence therapeutics signs collaboration agreement with Orano to develop the next generation of targeted radio-immunotherapy for cancerDefence’s Pipeline Advances To Multiple Phase I Clinical TrialsDefence Delegates City Of Hope To Initiate Ind Filing For Its Accutox™ Cancer ProgramDefence Manufacturing Its ARM™ Vaccine In Preparation For Phase I Clinical Trial Against Solid TumorsDefence’s lung cancer GLP tox study on its intranasal accutox™ formulation advancesDefence's Melanoma Targeted Vaccine A1 – Reprogrammed MSC (ARM™) Cell Potency ValidatedDefence’s to Present at the 9th Annual Immuno-oncology 360° Summit in New York February 7–10, 2023Defence’s Accum™ Accepted US Patent to Bolster its Vaccine Platform Technology IP mRNA with Defence’s Accum™ Program has Been Initiated2022 Breakthrough Results: Defence Novel Accutex™ Intranasal Reduced 50% of Cancer Nodules on Aon Animals with Lung TumorsDefence’s mRNA with Accum™ for Cancer Vaccines UpdateDefence positioned to begin its anti-cancer Accutox™ phase i trial with successful completion of GLP studiesDefence’s successfull study on the accuvac-pt007 vaccine targeting cervical cancerDefence Therapeutics completes fully-subscribed debenture financing of $2,355,000Defence to apply its propriatry Accum™ technology in The design of messenger RNA anti-cancer vaccines Defence therapeutics announces debenture financingDefence Therapeutics initiates lung cancer treatment program with its novel accutox™ formulation via intranasalDefence therapeutics is granted patents in Japan and Israel expanding its novel ADC platform technology in the fast growing antibody-drug conjugates marketBreakthrough results with accum™ A1 reprogrammed MSC, Mesenchymal stem cells, in a novel vaccine cured 80% of animals with pre-established lymphomaDefence Therapeutics applauds United States President Biden cancer Moonshot initiativeBREAKTHROUGH DISCOVERY: Defence Accum™ Variant "A1" converts mesenchymal stromal cells into potent antigen presenting cells suitable for cancer vaccination Defence Therapeutics receives U.S. patent covering its ADC platform technologyBREAKTHROUGH DISCOVERY: Accutox™ effective kills cancer cells by directly eliciting DNA damageDefence's Accum™ with antibody drug conjugates (ADC) in development against cancer Defence reports effective control of cervical cancer growth in response to its ACCUVACC-PT007 Therapeutic VaccinationDefence's novel ACCUVAC-PTE7 vaccine shows complete protection from cervical cancerDefence Therapeutics announces issuance of a U.S. patent covering its pioneering vaccine platform technologyDefence Therapeutics: An anti-cancer solutions platform company advancing its versatile Accum TechnologyDefence releases peer-reviewed publication of its preclinical data on ACCUVAC-D001L in cell reports medicine journalDefence retains CATO SMS to advise on its Phase I clinical trial on ACCUTOX™ for breast cancerDefence’s AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9Defence Therapeutics achieves a major milestone and begins IND-enabling testing of its accutox lead compound against breast cancer2021 Defence therapeutics reports successful completion of its covid-19 vaccine accuvac-pt001 toxicology studies in rabbits Defence therapeutics appoints dr. Riam shammaa to its board of directorsDefence therapeutics development program to engineer a new hpv vaccine initiated Defence therapeutics receives dtc eligibility Defence therapeutics signs a collaboration agreement with the curie institute for testing the accum-t-dm1 adc therapeutic in pdx models of breast cancerDefence therapeutics, strong therapeutics pipeline: adc’s, cancer and covid vaccines Defence therapeutics advances in pre-clinical testing of its infectious disease vaccine programDefence therapeutics accumtm boosts by 9-fold the delivery effectiveness of the crispr/cas9 protein to target cellsDefence therapeutics vaccines and program developmentDefence therapeutics cancer vaccine accuvac-d001 manufacturing targets melanoma and breast cancer Defence therapeutics accumtm variants in vitro study increases the potency of t-deruxtecan adc by 5-fold on breast cancerDefence therapeutics to finalize its objectives to initiate a phase i trial against breast cancerDefence therapeutics prepares for phase I trial to test its dc cancer vaccine, accuvac-d002, against melanomaDefence therapeutics successfully engineered and tested a novel intranasal covid-19 vaccine formulation in animalsDefence therapeutics success in testing its covid-19 accuvac-pt001 vaccine in a non-rodent modelDefence therapeutics files acid-based hydrogels usa provisional patent application Defence therapeutics selects the best 8 accumtm variants to optimize its adc therapeuticThe antibody response induced by defence therapeutics accuvac-pt001 vaccine cross-reacts with all tested sars-cov-2 variantsDefence therapeutics signs an agreement with biopharma excellence a pharmalex gmbh company, to maximize and strategize the development of its accumtm platform and clinical trials Defence therapeutics accutox exhibits potent anti-cancer propertiesDefence therapeutics retains the hus comprehensive cancer center to optimize its accum-t-dm1 adc therapeuticDefence therapeutics accuvac-d001 cancer vaccine generates effective long-lasting anti-tumoral response
